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We demonstrate the theoretical and practical application of
modern kernel-based machine learning methods to ligand-
based virtual screening by successful prospective screening
for novel agonists of the peroxisome proliferator-activated
receptor g (PPARg)[ 1 ] .P P A R g is a nuclear receptor
involved in lipid and glucose metabolism, and related to
type-2 diabetes and dyslipidemia. Applied methods
included a graph kernel designed for molecular similarity
analysis [2], kernel principle component analysis [3],
multiple kernel learning [4], and, Gaussian process
regression [5].
In the machine learning approach to ligand-based vir-
tual screening, one uses the similarity principle [6] to
identify potentially active compounds based on their
similarity to known reference ligands. Kernel-based
machine learning [7] uses the “kernel trick”, a systematic
approach to the derivation of non-linear versions of lin-
ear algorithms like separating hyperplanes and regres-
sion. Prerequisites for kernel learning are similarity
measures with the mathematical property of positive
semidefiniteness (kernels).
The iterative similarity optimal assignment graph
kernel (ISOAK) [2] is defined directly on the annotated
structure graph, and was designed specifically for the
comparison of small molecules. In our virtual screen-
ing study, its use improved results, e.g., in principle
component analysis-based visualization and Gaussian
process regression. Following a thorough retrospective
validation using a data set of 176 published PPARg
agonists [8], we screened a vendor library for novel
agonists. Subsequent testing of 15 compounds in a
cell-based transactivation assay [9] yielded four active
compounds.
The most interesting hit, a natural product derivative
with cyclobutane scaffold, is a full selective PPARg ago-
nist (EC50 = 10 ± 0.2 μM, inactive on PPARa and
PPARb/δ at 10 μM). We demonstrate how the interplay
of several modern kernel-based machine learning
approaches can successfully improve ligand-based virtual
screening results.
Author details
1University of Frankfurt, Siesmayerstr. 70, 60323 Frankfurt am Main, Germany.
2Berlin, Germany.
Published: 4 May 2010
References
1. Henke B: Progress in Medicinal Chemistry 2004, 42:1-53.
2. Rupp M, Proschak E, Schneider G: J Chem Inf Model 2007, 47(6):2280-2286.
3. Schölkopf B, Smola A, Müller K-R: Neural Comput 1998, 10(5):1299-1319.
4. Sonnenburg S, Rätsch G, Schäfer C, Schölkopf B: J Mach Learn Res 2006,
7(7):1531-1565.
5. Rasmussen C, Williams C: MIT Press, Cambridge 2006.
6. Johnson M, Maggiora M: Wiley, New York 1990.
7. Schölkopf B, Smola A: MIT Press, Cambridge 2002.
8. Rücker C, Scarsi M, Meringer M: Bioorg Med Chem 2006, 14(15):5178-5195.
9. Rau O, Wurglics M, Paulke A, Zitzkowski J, Meindl N, Bock A, Dingermann T,
Abdel-Tawab M, Schubert-Zsilavecz M: Planta Med 2006, 72(10):881-887.
doi:10.1186/1758-2946-2-S1-P27
Cite this article as: Rupp et al.: Kernel learning for ligand-based virtual
screening: discovery of a new PPARg agonist. Journal of Cheminformatics
2010 2(Suppl 1):P27.
1University of Frankfurt, Siesmayerstr. 70, 60323 Frankfurt am Main, Germany
Rupp et al. Journal of Cheminformatics 2010, 2(Suppl 1):P27
http://www.jcheminf.com/content/2/S1/P27
© 2010 Rupp et al; licensee BioMed Central Ltd.